A drug is sometimes used at a low dose strength rather than a high one in order to reduce the cumulative dose to which the patient is exposed, thereby lessen* ing any dose-dependent adverse effects. What if this low-strength product actually delivers a higher dose? An imiquimod cream at a strength of 3.75 (Zyclara°) was introduced to the market in 2021 for patients with troublesome actinic keratosis (see opposite). A 5 imiquimod cream (Aldara°) had already been on the market since the 2000s, and was authorised for use in the same clinical situation.
展开▼
